The other groups received tumor cells, Dual-RevCAR T-cells together with either RevTM CEA-IgG4-7B6, RevTM EpCAM-IgG1-5B9 or a combination of both RevTMs. This evidence concerns the gene CEACAM5 and neoplasm.